BeiGene

Tislelizumab (BGB-A317) is an investigational humanized IgG4 monoclonal antibody designed to bind to and inhibit PD‑1. Tislelizumab is being developed as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers.

BeiGene

Ociperlimab (BGB-A1217) is an investigational humanized monoclonal antibody designed to bind to TIGIT. BeiGene is currently evaluating ociperlimab in combination with anti-PD-1
monoclonal antibody tislelizumab in a broad range of advanced or metastatic solid tumors.

BeiGene

Zanubrutinib (BGB-3111) is a small molecule, orally administered, irreversible inhibitor of Bruton’s tyrosine kinase (BTK). Watch the mode of action (MoA) video to learn more.

Chat with BeiGene

Close